Le Lézard
Classified in: Health
Subject: PLW

Syneron Candela Announces Updates In Patent Infringement Cases


WAYLAND, Mass., Nov. 7, 2018 /PRNewswire/ -- Syneron Medical Ltd and its subsidiary Candela Corporation (collectively, Syneron Candela), a leading global aesthetic device company announced updates today to several patent infringement lawsuits.   In April 2018,  defending its Profound RF based Microneedle product,  Syneron Candela filed patent infringement complaints against 18 manufacturers and distributors of fractional RF micro-needle dermatological treatment systems in both the U.S. International Trade Commission in Washington, D.C. and in federal district court.  The accused infringing products include Secret RF by ilooda Co., Ltd. and Cutera, Inc.; Fraxis Duo by ilooda Co., Ltd., Emvera Technologies, LLC and Rohrer Aesthetics, LLC; Fractora by Invasix Ltd., Invasix, Inc. and InMode MD Ltd.; Legend Pro by Lumenis Ltd and Pollogen Ltd; 3DEEP by EndyMed Medical Ltd. and EndyMed Medical Inc.; INTRAcel by Jeisys Medical, Inc. and Perigee Medical LLC; Infini by Lutronic, Corp. and Lutronic, Inc.; and Vivace by Sung Hwan E&B Co. Ltd, Aesthetics Biomedical, Inc. and Cartessa Aesthetics LLC. The lawsuit filed with the ITC seeks to block importation into the U.S. of all fractional RF micro-needle products and is currently scheduled for trial on May 6, 2019. 

(PRNewsfoto/Candela)

Unrelated to the above mentioned fractional RF micro-needling case, a patent infringement lawsuit concerning Sublative technology and involving different patents initiated in January 2016 by Syneron Candela's former owners against InMode Ltd and Invasix in the US District Court for the Central District of California recently resulted in the asserted claims of those unrelated patents being held invalid over prior art. On the same day that judgment was entered, the company filed an appeal with the Court of Appeals for the Federal Circuit.  Syneron Candela intends to vigorously pursue its pending appeal concerning its Sublative patents.

"Dr. Dieter Manstein, at Massachusetts General Hospital, is the inventor on the two patents being asserted in the fractional RF micro-needle litigation filed with the International Trade Commission. Those two patents  protecting our Profound RF based Microneedle product were not involved in the Sublative litigation," says Geoffrey Crouse, CEO of Syneron Candela.

"In addition to our heavy investment in developing groundbreaking technologies, the core of our market approach centers around building clinical trust with our customers and using our technology to change lives.  Through our twelve recently launched National Centers of Excellence across North America and Canada dedicated to sharing clinical excellence, we continue to develop and expand the knowledge and patient access to our market-leading technologies, such as the Vbeam Prima, Gentle Pro Series, Profound and Picoway.  We take our commitment to protecting our technology and the trust of our physician partners seriously and will continue to strongly defend our patents," concludes Mr. Crouse. 

Candela®
Candela is a leading global aesthetic device company with an extensive product portfolio and expansive global commercial footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, tattoo removal, women's health treatments, facial resurfacing, traumatic and surgical scar treatments, body contouring, improving the skin's appearance through the treatment of benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Candela has a wide portfolio of trusted, leading products, including Vbeam®, the Gentle Family®, CO2RE®, CO2RE Intima®, Profound®, el?s Plus®, PicoWay®, UltraShape®, VelaShape®, IPL and other laser-based platforms. Acquired by Apax Partners in July 2017, the Company markets, services and supports its products in 86 countries. It has offices in the United States, Australia, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Portugal, Spain and the United Kingdom and many international distributors.

Media Contact:
EvolveMKD
P: 646.517.4220 | E: [email protected]

 

SOURCE Candela


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: